Two years after first announcing the partnership, Boehringer Ingelheim and software firm Veeva Systems have launched Boehringer’s One Medicine platform to help the German pharma streamline its product development by bringing together clinical, regulatory and quality data processes.
Boehringer plans to use One Medicine to boost its development of new medicines, the company said in a March 11 release, by linking data across functions and improving trial efficiency and collaboration with research sites.
Related
Lonza's Synaffix adds Boehringer to its constellation of partners with $1.3B ADC tech pact
"Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world," Oliver Fink, Boehringer’s head of learning, process and digitalization, said in the release.
The platform is powered by Veeva’s development cloud, which includes applications for clinical trial management, quality management and payments, among other R&D needs.
Boehringer and Veeva started the One Medicine collaboration in March 2022, building on a prior decades-long commercial partnership, Boehringer said in a March 2022 release.
Veeva’s tech is used by more than 450 companies, including pharmas like Merck and Eli Lilly and CROs like Parexel and Fortrea, according to the company’s website. The firm teamed up with Fortrea and regulatory review company Advarra in January 2024 in an effort to streamline and reduce the administrative burden of trials run by Fortrea.